Abbott ABT Established Pharmaceuticals — Depreciation

Other segment segments

Similar metrics at other companies

IFFPharma Solutions — D&A

$34.25M-1.4%

WSTContract-Manufactured Products — Depreciation, Depletion and Amortization

$7.6M+22.6%

WSTProprietary Products — Depreciation and Amortization

$36.4M+11.3%

LHBiopharma Laboratory Services — Depreciation

$28.6M0.0%

ZTSOperating Segments — D&A

$19M+5.6%

ATIOperating Segments — Depreciation

$40.2M-5.6%

Questions, answered.

What is Abbott's established pharmaceuticals — depreciation?

Abbott (ABT) reported established pharmaceuticals — depreciation of $30M in Q1 2026.

How has Abbott's established pharmaceuticals — depreciation changed year-over-year?

Abbott's established pharmaceuticals — depreciation increased by 30.4% year-over-year, from $23M to $30M.

What is the long-term trend for Abbott's established pharmaceuticals — depreciation?

Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — depreciation has grown at a 1.8% compound annual growth rate (CAGR), from $94M to $101M.

What does established pharmaceuticals — depreciation mean?

The non-cash expense representing the wear and tear of physical assets used by the segment.

How do you interpret established pharmaceuticals — depreciation?

High depreciation relative to assets may indicate a capital-intensive business or aging infrastructure requiring replacement.

How does established pharmaceuticals — depreciation compare across companies?

Standard depreciation expense reported in segment notes for manufacturing-heavy businesses.